The primary objective of this study is to determine if a single intravenous (IV) dose of MK-1654 when administered at 1 of 4 dose levels results in a reduction in viral load after intranasal inoculation (with RSV A Memphis 37b) compared to IV placebo. It is hypothesized that at least 1 of the 4 dose levels of MK-1654 given prior to inoculation will reduce the area under the viral load-time curve (VL-AUC) from Day 2 through Day 11 (inclusive) compared to placebo.
Full Title of Study: “A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated With Experimental Respiratory Syncytial Virus”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Study Primary Completion Date: February 24, 2020
- Biological: MK-1654
- MK-1654 in 100 mg/mL vials for IV infusion.
- Other: Placebo
- Placebo (0.9% sodium chloride, USP sterile saline) for IV infusion.
- Biological: RSV-A Memphis 37b
- Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b for intranasal administration.
Arms, Groups and Cohorts
- Experimental: MK-1654 100 mg
- Participants receive a single IV infusion of MK-1654 100 mg on Day 1.
- Experimental: MK-1654 200 mg
- Participants receive a single IV infusion of MK-1654 200 mg on Day 1.
- Experimental: MK-1654 300 mg
- Participants receive a single IV infusion of MK-1654 300 mg on Day 1.
- Experimental: MK-1654 900 mg
- Participants receive a single IV infusion of MK-1654 900 mg on Day 1.
- Placebo Comparator: Placebo
- Participants receive a single IV infusion of placebo on Day 1.
Clinical Trial Outcome Measures
- Max Area Under the Viral Load-time Curve (VL-AUC)
- Time Frame: From Day 2 through Day 11 (inclusive)
- The VL-AUC will be determined by reverse transcription qualitative integrated cycler polymerase chain reaction (RT-qPCR) after viral inoculation.
- Incidence of Symptomatic RSV Infection
- Time Frame: From Day 2 to Day 11 (inclusive)
- Symptomatic RSV infection is defined as presence of at least 2 quantifiable RT-qPCR at ≥2 consecutive days, plus symptoms of either any grade from 2 different symptoms from the subject symptom card (SSC) or at least one Grade 2 symptom from ≥1 respiratory categories.
- Number of Participants with an Adverse Event (AE)
- Time Frame: Up to 90 days
- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Number of Participants with a Serious Adverse Event (SAE)
- Time Frame: Up to 90 days
- An SAE is any untoward medical occurrence in a clinical study participant that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event.
- Serum Concentration of MK-1654
- Time Frame: Days 1, 18, 15, 29, 40, and 57
- The post-dosing concentration of MK-1654 will be determined in serum. On Day 1, 3 samples will be taken at 1, 2, and 4 hours after administration.
- Concentration of RSV Serum Neutralizing Antibody Titers
- Time Frame: Days 1, 29, 40, and 57
- The concentration of RSV serum neutralizing antibody titers will be determined with enzyme-linked immunosorbent assay (ELISA) after intranasal inoculation with RSV Memphis 37b.
Participating in This Clinical Trial
- Is a male or female 18 to 55 years of age in good health with no history of major medical conditions that will interfere with participant safety, as defined by medical history, physical examination (including vital signs), electrocardiogram (ECG), and routine laboratory tests and determined by the Investigator at a screening evaluation.
- Has a total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m^2 and ≤ 30kg/m^2.
- If male, agrees to study contraceptive requirements at dosing and continuing until 90 days after dosing or 28 days after viral inoculation (whichever is later) and to not donate sperm until 90 days after dosing.
- If female, has a negative pregnancy test at screening and prior to dosing and agrees to use one form of highly effective contraception if a woman of chilbrearing potential (WOCBP), or is not a WOCBP.
- Has serology results within 90 days of dosing that suggest the participant is sensitive to RSV infection (i.e., that they are likely to become infected following inoculation).
- Is a female who is breastfeeding or has been pregnant within 6 months prior to enrollment.
- Has a history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunesuppression), metabolic, urological, renal, neurological, or psychiatric disease (including participants with a history of depression and/or anxiety with associated severe psychiatric comorbidities.
- Has any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and in particular any of the nasal assessments or viral inoculation (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month will be excluded).
- Has any clinically significant history of epistaxis (large nosebleeds) within the last 3 months prior to IMP dosing and/or history of being hospitalized due to epistaxis on any previous occasion.
- Has a history or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks prior to dosing.
- Has any other major disease that, in the opinion of the Investigator, may interfere with a participant completing the study and necessary investigations.
- Has a history of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the investigator.
- Has confirmed positive test for drugs of abuse prior to randomization.
- Has a history or presence of alcohol addiction, or excessive use of alcohol (weekly intake in excess of 28 units alcohol; 1 unit being a half glass of beer, a small glass of wine or a measure of spirits), or excessive consumption of xanthine containing substances (e.g. daily intake in excess of 5 cups of caffeinated drinks e.g. coffee, tea, cola).
- Is positive for human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test.
- Has evidence of receipt of vaccine within the 4 weeks prior to IMP dosing.
- Has intention to receive any vaccine(s) before the last day of Follow-up.
- Receipt of blood or blood products, or loss (including blood donations) of 470 mL or more of blood during the 3 months prior IMP dosing or planned during the 3 months after the final visit.
- Has use within 7 days prior to IMP dosing of any medication or product (prescription or over-the-counter), for symptoms of hay fever, dermatitis, nasal congestion or respiratory tract infections including the use of regular nasal or dermal corticosteroids or antibiotics, apart from those allowed in the study.
- Has received systemic (intravenous and/or oral) glucocorticoids or systemic antiviral drugs within 6 months prior to IMP dosing.
- Has received chronic (defined as more than 14 continuous days) or current administration of a systemic immunosuppressant or other immune modifying drug, including any dose of oral corticosteroids, within 6 months prior to dose administration. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
- Has used or anticipated use during the conduct of the study of concomitant medications (prescription and/or non-prescription), including vitamins or herbal and dietary supplements within the specified windows (within 7 days prior to IMP dosing), unless in the opinion of the Principal Investigator, the medication will not interfere with the study procedures, outcomes, or compromise participant safety.
- Has a history (participant recall) of receiving any human immunoglobulin preparation
- Has received any investigational drug within 3 months prior to IMP dosing.
- Has received ≥3 investigational drugs within the previous 12 months prior to IMP dosing.
- Has prior participation in another Human Viral Challenge study with a respiratory virus of the same virus family in the preceding 3 months taken from the date of viral challenge in the previous study to the date of expected viral inoculation in this study.
- Has prior participation in any RSV related (vaccine, monoclonal antibody or small molecule) interventional trial.
- Has a forced expiratory volume in 1 second (FEV1) < 80%.
- Has presence of fever, defined as participant presenting with a temperature reading of ≥ 37.9 oC on day of IMP dosing.
- Has smoked ≥ 10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years]).
- Has venous access deemed inadequate for the phlebotomy and demands of the study.
- Presents any concern by the investigator regarding safe participation in the study or for any other reason the investigator considers the participant inappropriate for participation in the study.
- Has any contraindication for IV infusion.
- Is or has Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 55 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Merck Sharp & Dohme Corp.
- Provider of Information About this Clinical Study
- Overall Official(s)
- Medical Director, Study Director, Merck Sharp & Dohme Corp.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.